CLINICAL PHARMACOLOGICAL APPROACH TO THE USE OF ANTICOAGULANT DRUGS IN ISCHEMIC HEART DISEASE

The article discusses approaches to the choice of antithrombotic therapy (AT) in patients with non-valvular atrial fibrillation (AF) and coronary heart disease (CHD) both in acute coronary syndrome (ACS) and stable forms, including those who have undergone percutaneous coronary intervention. Determination of the regimens and duration of AT depend on the form of CHD, the risk of bleeding, and the anatomy of the implanted stents in the coronary arteries. In the composition of AT in modern regulatory documents, any oral anticoagulant is recommended for patients with CHD and AF: vitamin K antagonists, direct thrombin inhibitor - dabigatran, selective factor Xa inhibitors of coagulation - rivaroxaban, apixaban.